Contact Us
Contact Us
Contact Us


Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.

Race Oncology

Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).

ASX Announcements

27/02/2020Appendix 2ADownload
27/02/2020Cleansing NoticeDownload
25/02/2020Appendix 4D & Half-Year Financial StatementsDownload
20/02/2020Race significantly strengthens Clinical Advisory BoardDownload
17/02/2020Appendix 3GDownload
17/02/2020Race appoints Australian Clinical Program DirectorDownload
03/02/2020Appendix 3X-Prof Borje AnderssonDownload
30/01/2020December 2019 Quarterly ReportDownload
28/01/2020Appendix 3BDownload
28/01/2020Clarification AnnouncementDownload
1  2  3  4  5  6  



Latest News

Read All Stories

Don't miss important updates

Get the latest news & announcement and stay up-to-date.

© 2020 Race Oncology. Website By Multiplier